"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial of CB 1954 and EP-0125R for advanced cancer (PH1/088)
This trial looked at a new drug called CB 1954 in combination with a chemical called EP-0125R to treat advanced cancer. This trial was supported by Cancer Research UK.
Advanced cancer can be very difficult to treat. So doctors are always looking for new treatments. In this trial doctors looked at an experimental treatment to see how well it worked for people with advanced cancer.
A ‘pro drug’ is a drug that is not active on its own. But it becomes active when given with another substance. CB 1954 is a pro drug. It turns into an active drug in the body, but only in combination with EP-0125R.
In this trial, patients with advanced cancer had both EP-0125R and CB 1954. The doctors in this trial hoped that EP-0125R will help change CB1954 into an active drug inside the cancer cells, and kill them.
The aims of this trial were to find out
- The best doses of CB1954 and EP-0125R to give
- More about the side effects
- What happens to CB 1954 and EP-0125R inside the body
- How well it works
Summary of results
The researchers found a safe dose of CB 1954 and EP-0125R that didn’t cause too many side effects.
There were 32 people who took part in this trial. They had different types of advanced cancer, but all had cancer that had continued to grow despite treatment. Everybody had CB 1954 and EP-0125R.
The first few patients had very low doses of CB 1954 and EP-0125R. As they didn’t have any bad side effects, the next few people had a higher dose, and so on. By doing this, the researchers were able to work out the highest dose they could use without causing bad side effects.
The researchers also looked at the effect CB1954 and EP-0125R had on advanced cancer. In most people, they could not see a response to the drug. But in 3 people the cancer stayed the same size – researchers call this
The main side effects of both drugs included nausea, vomiting, anorexia, diarrhoea, dehydration and liver problems.
We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Professor Mark Middleton
Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
This is Cancer Research UK trial number CRUKD/04/035.